Straits Times Index
3,292.82 +0.13 (+0.00%) Nikkei
38,239.58 -34.47 (-0.09%) Hang Seng
18,196.21 +433.18 (+2.44%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,386.78 -2,528.84 (-4.22%) CMC Crypto 200
1,257.55 -81.52 (-6.09%)
LLY Jun 2024 490.000 call
| Previous close | 263.00 |
| Open | 263.00 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 490.00 |
| Expiry date | 2024-06-21 |
| Day's range | 263.00 - 263.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Yahoo Finance3 stocks with the biggest gains took April's biggest losses
The stock market's very rough April saw some of the biggest gainers of the first three months take some of the biggest dings to their market caps. And at the same time, some of the sectors that struggled in Q1 saw a similar reversal of fortune in April.
- Reuters
FOCUS-British pharmacies vie for weight-loss patients with drug price cuts
Online pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just months after the weight-loss drugs were launched there, as initial supply shortages ease. But growing competition between retailers has raised fears that some patients who buy the drugs themselves, rather than relying on the National Health Service (NHS), will miss out on long-term aftercare if they keep switching providers.
ZacksETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
